Allarity Therapeutics, Inc. (ALLR)

Current Report Filed: 2026-04-28

USPTO issued a Notice of Allowance for Allarity's DRP® companion diagnostic patent application specific to stenoparib, which strengthens intellectual property protection for a key diagnostic asset tied to their drug development pipeline.
The patent allowance for a companion diagnostic is strategically significant as it provides regulatory and competitive moats for stenoparib commercialization, potentially enabling precision medicine positioning and differentiation in the market.
As an emerging growth company, Allarity is building patent coverage that could support future partnering opportunities, licensing deals, or standalone commercialization of both the therapeutic and diagnostic components.

Current Report Filed: 2026-04-22

Allarity Therapeutics announced publication of two scientific posters at the AACR Annual Meeting 2026, indicating ongoing research progress and clinical development activities in oncology.
The filing is classified as 'Other Matters' under Item 8.01, suggesting this is a routine announcement of scientific presentations rather than a material corporate event or financial disclosure.
As an emerging growth company, Allarity continues to leverage scientific conferences for visibility and validation of its therapeutic pipeline, though the 8-K provides no details on the specific research findings or clinical implications.

Current Report Filed: 2026-04-01

Allarity Therapeutics, Inc. has reported its financial results for the fiscal year ended December 31, 2025. This information is material to investors as it provides an update on the company's financial performance and condition.
The company's press release containing the financial results has been attached as an exhibit to the 8-K filing, allowing investors to review the detailed financial information.
As an emerging growth company, Allarity Therapeutics has the option to take advantage of the extended transition period for complying with new or revised financial accounting standards, which could impact its future financial reporting.

Annual Report Filed: 2026-03-30

The company is focused on improving its IT governance and cybersecurity practices, with regular review and oversight from senior leadership and the board of directors.
The company does not appear to have reported any recent cybersecurity incidents, indicating a proactive approach to managing cyber risks.
The company's disclosure indicates a strong commitment to transparency and risk management in the area of information technology and cybersecurity.

Current Report Filed: 2026-03-09

Allarity Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital, which provides additional funding to support the company's ongoing operations and development efforts.
The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards, indicating a focus on timely compliance with reporting requirements.
The filing does not provide any information about the company's financial performance, product pipeline, or other strategic developments, limiting the insights that can be derived from this 8-K filing alone.

Current Report Filed: 2026-03-06

Allarity Therapeutics, Inc. entered into a $20.93 million note purchase agreement with Streeterville Capital, LLC, which includes a $10.93 million promissory note and a $10 million secured promissory note.
The note purchase agreement allows for a potential note exchange where the company can exchange $2.5 million of the $10 million B Note for an A Note, providing more flexibility in managing the debt.
The notes carry interest rates of 9% and 5% per annum, respectively, and have a maturity of 18 months, with the company having the ability to prepay the notes at any time.

Current Report Filed: 2026-02-04

Allarity Therapeutics has initiated a new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer, which could expand the company's pipeline and treatment options.
The company's announcement of the new clinical trial enrollment opening indicates continued progress in its drug development efforts and a commitment to advancing its pipeline.
As an emerging growth company, investors should monitor Allarity Therapeutics' future financial and operational performance as the company continues to develop its therapies.

Current Report Filed: 2026-01-29

Allarity Therapeutics entered into a $6 million common stock purchase agreement with Tumim Stone Capital, providing the company access to additional capital through a flexible equity line facility.
The agreement includes an 'Exchange Cap' that limits the number of shares Allarity can issue under the facility to 19.99% of the current outstanding shares, unless shareholder approval is obtained.
Allarity will need to submit proposals to shareholders at the next annual meeting to approve a waiver of the Exchange Cap and potentially increase the authorized shares, in order to fully utilize the equity line.

Insider Trading Filed: 2026-01-16

Jeremy R. Graff, the President and Chief Development Officer of Allarity Therapeutics, Inc., has acquired 133,333 shares of the company's common stock in a direct transaction, increasing his beneficial ownership to 381,644 shares.
The restricted stock units (RSUs) granted to Graff are subject to a vesting schedule, with one-third of the RSUs vesting on each of the first, second, and third anniversaries of the grant date, contingent on his continued relationship with the company.
The insider transaction indicates Graff's confidence in the company's future prospects and aligns his interests with those of shareholders.

Important Information